The complaint, currently being litigated by Faruqi & Faruqi, LLP, targets the period between February 13, 2025, and May 14, 2026. Plaintiffs allege that Aardvark executives provided materially false or misleading information to the market, obscuring risks associated with the clinical and regulatory prospects of ARD-101. The legal challenge gained momentum following a 32% drop in the company's share price on May 15, 2026, which occurred after corrective disclosures surfaced.
In section Releases
Aardvark Therapeutics Investors Face October Deadline in Class Action
Investors holding Aardvark Therapeutics stock have until October 13, 2026, to seek lead plaintiff status in a federal securities class action. The lawsuit follows allegations that the company misled shareholders regarding the safety and commercial viability of its lead drug candidate, ARD-101, during its 2025 initial public offering.
Those who acquired shares during the Class Period or through the IPO documents may contact partner Josh Wilson to discuss potential claims. While the court-appointed lead plaintiff will oversee the litigation on behalf of the class, participation in the suit remains optional for other affected investors. The firm is also seeking information from former employees and whistleblowers as the case proceeds toward the October filing deadline.
Comments (0)
No comments yet. Be the first!